CO2RE Intima Now First In-Office Laser Procedure CE Marked
for the Treatment of Vaginal Atrophy and Rejuvenation
IRVINE, California,
March 27, 2017 /PRNewswire/
-- Syneron Medical Ltd. (NASDAQ: ELOS), a leading global
aesthetic device company, today announced that the company secured
the CE Mark for CO2RE Intima, making it the first
in-office laser procedure now CE marked for the treatment of
vaginal atrophy and rejuvenation. CO2RE Intima is a
simple non-surgical treatment that promotes vaginal wellness
amongst a broad array of women, while delivering a renewed sense of
confidence, comfort, quality of life and enhanced sexual
functioning. CO2RE Intima relieves the effects of
childbirth and aging by stimulating healing responses in the
vaginal canal to enhance moisture levels, while also remodeling the
tissue fibers in the vaginal and vulvar areas to restore their
flexibility and shape. It is also used to address changes and
symptoms associated with painful intercourse.
A survey of menopausal women showed that 75% suffered from
vaginal dryness, and 90% said it negatively affects their lives. In
the same survey, 63% of post childbirth women felt their vagina was
looser since giving birth and would consider a non-surgical
procedure to tighten their vaginal canal.1
"I have previously used other technologies for this type of
vaginal treatment, but the CO2 technology of
CO2RE Intima is more effective because it provides the
type of fractional impact that is most effective on mucosal
tissue," says César Arroyo, MD, head of the Medical Laser Unit in
HM Monteprincipe Hospital, Madrid,
Spain. "Additionally, it can be used to treat multiple areas
including the vaginal canal, introitus and vulva."
CO2RE Intima delivers favorable results, with mild to
no discomfort and little downtime. In a clinical study, conducted
by Dr. Arroyo, at the three-month follow-up after the third
treatment, 100% of women reported satisfaction with the treatment
and 94% would recommend it to others.2 Additionally, 82%
of the women showed a statistically significant improvement in the
vaginal health index (p<0.05).2 The treatment
requires no anesthesia and typically takes around 15 minutes to
treat. Most patients feel and see improvement after the very first
treatment; however, a series of three treatments, about four weeks
apart, is recommended for optimal results.
"We are proud to be the first company to secure the CE Mark for
the treatment of vaginal atrophy and rejuvenation," says Amit
Meridor, CEO of Syneron Candela. "CO2RE Intima's recent
CE Mark demonstrates Syneron Candela's continuing commitment to
innovation and leadership in aesthetic medicine, and now in the
women's intimate health category."
About Syneron Candela:
Syneron Candela is a leading global aesthetic device company with a
comprehensive product portfolio and a global distribution
footprint. The Company's technology enables physicians to provide
advanced solutions for a broad range of medical-aesthetic
applications including body contouring, hair removal, wrinkle
reduction, tattoo removal, women's intimate health, improving the
skin's appearance through the treatment of superficial benign
vascular and pigmented lesions, and the treatment of acne, leg
veins and cellulite. The Company has a wide portfolio of trusted,
leading products including UltraShape Power, VelaShape, CO2RE,
CO2RE Intima, GentleLase, VBeam Perfecta, PicoWay, Profound and
elōs Plus.
Founded in 2000, the corporate, R&D, and manufacturing
headquarters for Syneron Candela are located in Israel.
Syneron Candela also has R&D and manufacturing operations in
the U.S. The company markets, services and supports its
products in 86 countries. It has offices in North
America, France, Germany, Italy, Portugal, Spain,
UK, Australia, China, Japan, and Hong
Kong and distributors worldwide.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
This news
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 that involve
risks and uncertainties. Such forward-looking statements include
the expectations, plans and prospects for the Company, including
potential clinical successes, market acceptance of new products,
and projected revenues, margins, earnings and market shares. The
statements made by the Company are based upon management's current
expectations and are subject to certain risks and uncertainties
that could cause actual results to differ materially from those
described in the forward-looking statements. These risks and
uncertainties include the risk factors and other cautionary
statements described in the Company's filings with the SEC,
including those described in the Company's most recent Annual
Report on Form 20-F, and in the filings that Syneron Medical makes
with the SEC, and other factors beyond the Company's control. If
one or more of these factors materialize, or if any underlying
assumptions prove incorrect, Syneron Medical Ltd.'s actual results,
performance or achievements may vary materially from those
expressed or implied by these forward-looking statements. These
forward-looking statements should not be relied upon as
representing Syneron Medical Ltd.'s views as of any date after the
date of this document. The Company does not intend to update these
statements and undertakes no duty to any person to provide any such
update under any circumstance.
For additional information, please
visit http://www.syneron-candela.com.
Media contact:
Heidi
Donato, Cohn & Wolfe
E: Heidi.Donato@cohnwolfe.com
M: +1-516-359-1146
P: +1-516-221-0614
Investor Relations contact:
Zack Kubow, The Ruth Group
E: zkubow@theruthgroup.com
P: +1-646-536-7020
________________________________
1
Toluna Quick Study Survey, 2015.
2 3-month results from Clinical Study HM Monteprincipe
Hospital, Madrid, Spain, 2016 as
presented at the American Society for Laser Medicine & Surgery
(ASLMS) 2016 annual meeting.